@entity7923 treatment of XXXX of the mandible: @entity158 relief and insight into pathogenesis.

@entity1 @entity1568 @entity171 @entity4034 @entity7923 @entity5520 @entity89 @entity158 @entity479
PURPOSE: @entity4034 of the mandible (DSO) is a rare and poorly understood disease. Current treatment protocols, including @entity479 or analgesic medication and corticotomies, show poor or frustrating outcome results and are accompanied by potentially severe side effects. The aim of this study was to determine whether there is a beneficial role of infusions with @entity1568 -containing @entity171 ( @entity7923 ) in acute conditions of DSO. MATERIAL AND METHODS: Eleven @entity1 were enrolled in the study. In acute conditions of treatment-resistant DSO, single-shot infusions of @entity7923 (6  mg) were administered. @entity158 levels were documented 10 days before and after the infusion on a visual analogue scale (VAS). @entity1 were monitored regularly. RESULTS: Of the 11 @entity1 , 10 showed a distinct improvement in @entity158 (based on VAS scores) within 48-72  h after infusion. The @entity158 levels of the @entity1 were significantly lower after @entity7923 infusions (p  <  0.01). The majority of @entity1 were free or almost free of complaints over the following months. Four of the 11 @entity1 returned for repeated infusions. At the time of writing, no severe side effects have been observed, and in particular there has been no case of medication-related @entity89 . CONCLUSION: We conclude that single-shot @entity5520 infusions on demand are promising treatment alternatives in acute DSO. Single-shot @entity5520 infusions of @entity7923 were well tolerated and resulted in distinct, long lasting improvement in subjective @entity158 levels based on VAS scores.
